Ginkgo Bioworks Holdings annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Free Cash Flow (FCF) History (DNA)
Ginkgo Bioworks Holdings reported −$178.7M in free cash flow for fiscal 2025, an increase of $203.4M from the previous fiscal year, with a free cash flow margin of −105.04%.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$178.7M | $203.4M | — | −105.04% |
| 2024 | 2024-12-31 | −$382.1M | −$45.8M | — | −168.31% |
| 2023 | 2023-12-31 | −$336.3M | −$31.8M | — | −133.74% |
| 2022 | 2022-12-31 | −$304.5M | $5.9M | — | −63.74% |
| 2021 | 2021-12-31 | −$310.3M | −$116.7M | — | −98.89% |
| 2020 | 2020-12-31 | −$193.7M | −$126.8M | — | −252.62% |
| 2019 | 2019-12-31 | −$66.9M | — | — | −123.43% |
Ginkgo Bioworks Holdings quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$46.9M | −$6.6M | — | −232.65% |
| Q1 2026 | 2026-03-31 | −$48.6M | $10.5M | — | −249.66% |
| Q4 2025 | 2025-12-31 | −$47.7M | $8.5M | — | −88.38% |
| Q3 2025 | 2025-09-30 | −$31.6M | $87.0M | — | −81.38% |
| Q2 2025 | 2025-06-30 | −$40.3M | $71.1M | — | −102.96% |
| Q1 2025 | 2025-03-31 | −$59.1M | $36.8M | — | −154.70% |
| Q4 2024 | 2024-12-31 | −$56.1M | $5.1M | — | −128.05% |
| Q3 2024 | 2024-09-30 | −$118.6M | −$40.7M | — | −133.18% |
| Q2 2024 | 2024-06-30 | −$111.4M | −$24.4M | — | −198.24% |
| Q1 2024 | 2024-03-31 | −$96.0M | $14.1M | — | −252.92% |
| Q4 2023 | 2023-12-31 | −$61.3M | $68.9M | — | −176.31% |
| Q3 2023 | 2023-09-30 | −$77.9M | −$36.1M | — | −140.60% |
| Q2 2023 | 2023-06-30 | −$87.1M | $21.9M | — | −108.07% |
| Q1 2023 | 2023-03-31 | −$110.0M | −$86.5M | — | −136.34% |
| Q4 2022 | 2022-12-31 | −$130.2M | $40.5M | — | −132.45% |
| Q3 2022 | 2022-09-30 | −$41.8M | −$31.2M | — | −63.00% |
| Q2 2022 | 2022-06-30 | −$109.0M | −$50.0M | — | −75.36% |
| Q1 2022 | 2022-03-31 | −$23.5M | $46.6M | — | −13.94% |
| Q4 2021 | 2021-12-31 | −$170.7M | — | — | −114.92% |
| Q3 2021 | 2021-09-30 | −$10.7M | — | — | −13.75% |
| Q2 2021 | 2021-06-30 | −$58.9M | — | — | −135.08% |
| Q1 2021 | 2021-03-31 | −$70.1M | — | — | −158.89% |
Ginkgo Bioworks Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$193.7M to −$178.7M, a net increase of $14.9M. Ginkgo Bioworks Holdings's latest reported quarter, Q2 2026, generated −$46.9M in free cash flow, a decrease of $6.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Ginkgo Bioworks Holdings filings at SEC.gov ↗